Welcome, visitor! [ Login

Dragon Releases Third Quarter 2001 results

News

Dragon Pharmaceuticals Inc. announced results for the three months and nine months ending September 30, 2001. All dollar amounts are expressed in US currency.

Revenues for the quarter totalled $787,682, an increase of 6.5% over the same period in 2000. Revenues comprise sales of the company’s sole current product, Erythropoietin (EPO), which increased 115% to 157,067 doses compared to the same period last year. Revenues did not increase proportionately to sales volumes due to competitive EPO price reductions in China over the past year.

The third quarter represents the first sales revenue generated from outside China as the company delivered two shipments of vialed EPO to Egypt as well as a large order of purified bulk to Malaysia.

“We are in the product registration process for EPO throughout non-patent protected countries in Central and Eastern Europe, Southeast Asia, Latin America and the Middle East,” said Dr. Longbin Liu, President and Chief Executive Officer. “Our distribution partners have estimated the current market size in these areas at $310 million, which is expected to double by 2005.”

The loss for the quarter was $737,782 or $0.04 per share, compared to a loss of $362,975 or $0.03 per share in the third quarter 2000. The change was due to increased marketing and administration costs, and greater production of EPO to build inventories, in anticipation of international sales orders.

The company ended the quarter with cash and short-term investments of $9,372,683, compared with $6,340,315 at December 31, 2000.

For the first nine months of 2001, revenues totalled $2,054,437, a 6.5% decrease from the same period last year. This was in spite of a 66% increase in EPO sales to 400,222 doses. As with quarterly results, increased sales volumes did not translate into a proportionate revenue gain because of price erosion.

The company incurred a net loss of $2,566,678 ($0.15 per share) during the nine months, compared with $766,752 ($0.06 per share) for the same period in 2000.

Note: The term “dose” refers to the standard reference dosage of 2,000 IU.

Online Dragon Pharma Steroids

A one-stop resource for ordering Dragon Pharma samples: Buy NPP 150 on Sale – 24 hours a day, 7 days a week.

No Tags

11 total views, 1 today

  

  • Dragon Pharma Sells Polymun Development

    Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD) (“the Company”) announced today that the Company has sold its Development and Manufacturing Agreement with Polymun Scientific Immunbiologische Forschung GmBh (“Polymun”) to AS Biotech AG, a Swiss company, for US$1 million. Prior to the acquisition of Oriental Wave Holding Limited in early 2005, Dragon entered into a […]

  • Dragon Announces Growth in International EPO Sales

    Dragon Pharmaceuticals Inc. (NASDAQ OTC: DRUG) today announced the receipt of EPO sales orders from international markets outside of China totaling $937,500 in the first quarter of 2002, representing a 113% increase over total year international sales of $440,125 in 2001. To date, the Company has completed EPO shipments for $847,500 of first quarter orders, […]

  • Dragon Ships EPO Internationally

    Dragon Pharmaceuticals Inc. (NASDAQ OTC: DRUG) today announced that it has filled orders for recombinant erythropoietin (EPO) from Egypt, India and Peru where, in addition to China, the Company’s EPO is approved for use in the treatment of anemia related to chronic renal failure. All dollar amounts are stated in US dollars. “Penetrating new markets […]

  • Dragon Pharmaceutical Inc. Announces 2002 Fourth Quarter and Full Year Results

    Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced results for the three-month and twelve-month periods ending December 31, 2002. 2002 Highlights Generated revenues of $7.36 million, representing significant growth from $3.07 million in 2001. Enhancement of gross margin in 2002 to 86.7% from 81% in 2001. Reported a first ever operating profit of […]

  • Dragon Announces Participation at Biopartnering Europe 2001

    Dragon Pharmaceuticals Inc. (OTC BB – DRUG.OB) is pleased to announce that it has been invited to present at the BioPartnering Europe 2001 conference to be held at the Queen Elizabeth II Conference Centre in London, England from October 14th to 16th, 2001. BioPartnering Europe is the premier European venue for showcasing innovative biopharmaceutical and […]

Dragon Pharma Suppliers

dragon pharma source
american steroids online
real dragon pharma supplier
dragon pharma for sale
dragon pharma legit supplier
buy dragon pharma
dragon pharma store
buy steroids
dragon pharma legit dragon pharma anabolics